Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform
(Stockholm, Sweden, Sep. 8, 2020) Redwood Pharma is announcing today the launch of a new program to develop treatments based on IntelliGel to help patients suffering from mild dry eye. IntelliGel is the carrier used in the company’s RP101 estrogen therapy targeted at moderate-to-severe dry eye disease in post-menopausal women, which recently completed Phase II testing. In those Phase II trials (which were successful for RP101), the company’s scientists made the unexpected discovery that IntelliGel alone showed significant activity in safely relieving both signs and symptoms of dry eye